In the present study, the GalNAc-siRNA molecule RBD4059 showed promising reduction of FXI activity in preclinical animal models and antithrombotic effects without disrupting hemostasis.

RBD4059 is the first FXI-targeting GalNAc-siRNA molecule to reach the clinical stage of development and is a promising candidate for the development of a safe and efficient antithrombotic drug with high patient compliance.